Dementia - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

116 Pages (PDF)




Dementia - Pipeline Review, H1 2014

Summary

Global Markets Directs, Dementia - Pipeline Review, H1 2014, provides an overview of the Dementias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dementia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Dementia Overview 10
Therapeutics Development 11
Pipeline Products for Dementia - Overview 11
Pipeline Products for Dementia - Comparative Analysis 12
Dementia - Therapeutics under Development by Companies 13
Dementia - Therapeutics under Investigation by Universities/Institutes 16
Dementia - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Dementia - Products under Development by Companies 22
Dementia - Products under Investigation by Universities/Institutes 23
Dementia - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Sylentis S.A. 25
FORUM Pharmaceuticals Inc. 26
Ildong Pharmaceutical Co., Ltd. 27
SK Chemicals Co., Ltd. 28
WhanIn Pharmaceutical Co., Ltd. 29
Hyundai Pharmaceutical Co., Ltd. 30
Summit Corporation plc 31
Oryzon Genomics S.A. 32
Intellect Neurosciences, Inc. 33
Intra-Cellular Therapies, Inc. 34
Tautatis Incorporated 35
Pacific Northwest Biotechnology, LLC 36
Otsuka Holdings Co., Ltd. 37
Chase Pharmaceuticals Corporation 38
Echo Pharmaceuticals B.V. 39
Chronos Therapeutics Limited 40
Alector LLC 41
ImStar Therapeutics Inc. 42
Dementia - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 48
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
brexpiprazole - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
FRM-0334 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dronabinol - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ITI-007 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ARC-100 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
choline alfoscerate SR - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
TTT-3002 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules To Inhibit LSD-1 And MAO-B For Neurodegenerative Diseases - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
OG-45 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Seglin O-linked N-acetylglucosaminidase Inhibitors - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Gugulipid - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
RDC-5 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Peptide BACE Inhibitor - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
TauC3 Monoclonal Antibody - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Drugs For Dementia - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Drugs to Agonize c-MET for Dementia - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Drugs to Inhibit Matrix Metalloproteinase for Dementia And Cognitive Impairment - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
KR-12 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
OG-635 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Hexanoic-Tyrosine-Histidine-(6) Aminohexanoic Amide - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules for Age Related Cataracts, Macular Degeneration and Neurodegenerative Disorders - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecule to Inhibit Cathepsin B for Neurology disorders - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
IPN-007 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
NNC-269100 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimers Disease - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
IRL-752 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SID-111 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecule to Inhibit G Family for Dementia - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
WIB-1001C - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
T-01OX2 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecules to Activate Progranulin for Frontotemporal Dementia - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Antibodies for Dementia and Alzheimers Disease - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
CPC-252 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Dementia - Recent Pipeline Updates 98
Dementia - Dormant Projects 107
Dementia - Discontinued Products 108
Dementia - Product Development Milestones 109
Featured News & Press Releases 109
Mar 03, 2014: Intra-Cellular Therapies Announces Initiation of Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients with Dementia, Including Alzheimer's Disease 109
Jan 09, 2014: Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704 110
Oct 31, 2013: Eisai Submits Application to Expand Indication of Anti-alzheimer's Agent Aricept As Treatment for Dementia with Lewy Bodies in Japan 110
Oct 26, 2012: New Research Demonstrates Potential Of IRX4204 For Reduction Of Dementia In Animal Models Of Alzheimer's And Parkinson's Disease 111
Jul 16, 2012: Resverlogix Establishes Clinical And Scientific Advisory Board To Support Clinical Development Of RVX-208 111
Nov 08, 2011: NeuroSearch Publishes MermaiHD Study In The Lancet Neurology 112
Jun 30, 2011: NeuroSearch Provides Update On Clinical Development Program For Huntexil 112
Feb 23, 2011: Intellectual Property High Court of Japan Rules to Maintain Aricept Patent Term Extension in Relation to Severe Alzheimer's Dementia 112
Jul 24, 2010: Eisai Announces U.S. FDA Approval for New Higher Dose Aricept 23mg Tablet for the Treatment of Moderate-to-severe Alzheimers Disease 113
Jul 22, 2010: Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KGaA Settle NAMENDA Patent Litigation 114
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 116
Disclaimer 116
Bristol-Myers Squibb Company
Sylentis S.A.
FORUM Pharmaceuticals Inc.
Ildong Pharmaceutical Co., Ltd.
SK Chemicals Co., Ltd.
WhanIn Pharmaceutical Co., Ltd.
Hyundai Pharmaceutical Co., Ltd.
Summit Corporation plc
Oryzon Genomics S.A.
Intellect Neurosciences, Inc.
Intra-Cellular Therapies, Inc.
Tautatis Incorporated
Pacific Northwest Biotechnology, LLC
Otsuka Holdings Co., Ltd.
Chase Pharmaceuticals Corporation
Echo Pharmaceuticals B.V.
Chronos Therapeutics Limited
Alector LLC
ImStar Therapeutics Inc.				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement